Rockwell Medical Expands to 300 Customers, Forecasts $1–2M EBITDA and $100M Sales
Rockwell Medical expanded its dialysis concentrate base to 300 customers, secured a supply deal covering 70% of Innovative Renal Care clinics and launched FDA-approved bicarbonate cartridges to drive Q4 adjusted EBITDA profitability. It forecasts 2026 adjusted EBITDA of $1–2 million and targets over $100 million in annual sales by 2029.
1. Q4 Operational and Strategic Highlights
In Q4 2025 Rockwell aligned manufacturing to demand shifts, expanded its dialysis concentrate customer base to 300 accounts, including all five top U.S. dialysis providers and 30 international markets. It secured a multi-year agreement covering 70% of Innovative Renal Care clinics, improved structural margins through pricing discipline, and launched FDA-approved bicarbonate cartridges.
2. 2026 Financial Outlook and Growth Targets
For 2026 the company forecasts adjusted EBITDA of $1–2 million and positive operating cash flow. It anticipates growth in its Fresenius business, targets over $100 million in annual net sales by 2029, and aims for gross margins near 30% by shifting toward higher-margin ancillary products.
3. Q4 Financial Results and Guidance
Rockwell reported a Q4 net loss of $554,000, or $0.01 per share, on revenue of $18.3 million. For full-year 2025 it posted a $5.3 million loss, or $0.15 per share, on $69.3 million revenue and expects 2026 revenue between $65 million and $70 million.
4. Balance Sheet and Risk Factors
The company ended 2025 with $25 million in cash to fund strategic initiatives and acquisitions. It incurred $1.2 million in severance and restructuring charges and recognized $4 million in non-cash expenses, while extending its DaVita agreement through 2026 at increased pricing.